RFK Jr. confirmed by Senate as health secretary
Robert F. Kennedy Jr., a prominent vaccine critic who President Donald Trump has directed to “go wild” on healthcare, was...
Medicine
Aardvark prices $94M IPO to fund Prader-Willi, obesity drug work
Dive Brief: Aardvark Therapeutics on Wednesday night raised $94 million in an initial public offering that will support development of...
New study offers hints of GLP-1 drugs’ potential in curbing alcohol cravings
Scientists believe GLP-1 drugs like Novo Nordisk’s Ozempic help people with obesity lose weight in part because they can help...
Novartis pays $925M to reel in a startup it helped launch
Novartis is wagering more than $3 billion that a startup it helped launch six years ago has developed a better...
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
Today, a brief rundown of news involving Merck KGaA and BridgeBio Pharma, as well as updates from Biohaven, Third Harmonic...
Vertex COO Arbuckle to step down later this year
Stuart Arbuckle, Vertex’s chief operating officer and one of the company’s longest-tenured leaders, will retire from his role in July....
Pliant shares collapse as company halts fibrosis drug study
A committee of clinical trial monitors has advised Pliant Therapeutics to stop giving its experimental fibrosis drug to patients in...
Novo outlines new late-stage study of obesity drug CagriSema
Dive Brief: Novo Nordisk is planning a new Phase 3 trial of its next-generation obesity drug CagriSema that will test...
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Sales of Cobenfy, a new mind-stabilizing medicine, totaled $10 million in the final months of last year, results that fell...
Eli Lilly’s earnings, shares lifted by obesity drug sales
Dive Brief: Eli Lilly’s profit doubled in the fourth quarter as the Indianapolis-based drugmaker raked in revenue from diabetes and...
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
Dive Brief: Bristol Myers Squibb is expanding its plan to cut costs, announcing alongside quarterly earnings on Thursday that it...
Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty
Today, a brief rundown of news involving Mitsubishi Tanabe Pharma and Bausch + Lomb, as well as updates from Roche,...
Immune drugmakers Alumis and Acelyrin to merge
Dive Brief: Alumis and Acelyrin are merging, the biotechnology companies said Thursday afternoon, in an all-stock deal that leaves the...
Vertex challenger Sionna prices $191M IPO
Sionna Therapeutics on Thursday raised $191 million in an initial public offering that will fund its plan to challenge Vertex...
Pfizer taps a former Novartis exec to lead cancer drug push
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Pfizer on...
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb
Dive Brief: Sales of both GSK’s and Pfizer’s vaccines for respiratory syncytial virus dropped significantly in the last three months...
Flagship-backed Omega signals it’s headed toward bankruptcy
Dive Brief: Omega Therapeutics, a genetic medicines maker originally backed by Flagship Pioneering, plans to soon file for Chapter 11...
RFK Jr. secured support of key Republican with vaccine pledges
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Robert F....
Pfizer drug acquired in $11B buyout confirms benefit in colon cancer
Dive Brief: Adding Pfizer’s cancer drug Braftovi to standard treatments helped people with a form of colorectal cancer live longer...
Shares of psychedelics biotech nearly double on depression data
In a little more than a week’s time, a drug developed by a small psychedelics company was able to significantly...
Drugmakers prep for bird flu outbreak, despite continued low risk
An H5N1 outbreak is killing flocks of wild birds in Massachusetts and sickening dairy cows in 16 states while a...
23andMe considers a sale as cash runs low
Dive Brief: 23andMe said Tuesday it is exploring “strategic alternatives,” which could include the sale of the company, a business...
Christophe Weber, veteran Takeda CEO, to retire next year
Takeda CEO Christophe Weber plans to retire next year after a decade steering the Japanese drugmaker, a tenure in which...
RFK Jr. fumbles Medicare basics during second confirmation hearing
Robert F. Kennedy Jr., President Donald Trump’s health secretary nominee, showed limited knowledge about Medicare during his second confirmation hearing...
Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb
Today, a brief rundown of news involving Novartis and AbbVie, as well as updates from Biogen, Merck & Co. and...
A new, non-opioid pain drug is here. Getting it to patients could be agony.
For the last quarter century, one of the world’s most capable drug developers toiled to make a new, non-addictive kind...
Metsera, Maze secure combined $415 million in IPOs
Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and...
Vertex’s non-opioid pain drug gets FDA approval in milestone for company and research
The movement to steer pain treatment away from opioids notched a major victory Thursday, as the Food and Drug Administration...
RFK Jr. signals he’ll back Trump abortion policies, despite prior stance
Robert F. Kennedy Jr. on Wednesday told U.S. lawmakers that, if confirmed as the nation’s health secretary, he would support...
Democrats clash with RFK Jr. over vaccine views at heated Senate hearing
Democratic senators confronted Robert F. Kennedy Jr. on his positions concerning vaccines, health services and abortion during a contentious hearing...
Rival radiopharma drug to Novartis’ Lutathera succeeds in trial, ITM says
Dive Brief: A radiopharmaceutical medicine developed by Germany’s ITM outperformed everolimus, an older chemotherapy, in a late-stage study of people...
Lawmakers report states shut out of Medicaid payment portals following Trump funding freeze
Multiple lawmakers in Congress reported Tuesday that states were shut out of Medicaid payment portals after the Trump administration enacted...
Sage rebuffs Biogen bid to take it over
Dive Brief: Sage Therapeutics’ board of directors has turned back partner Biogen’s opportunitistic attempt at a takeover, unanimously rejecting a...
Akero says MASH drug reverses liver damage in study, doubling shares
Dive Brief: Treatment with an experimental drug from Akero Therapeutics substantially reversed liver damage in a mid-stage study of people...
BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors
Neil Kumar has for years contended his unorthodox drug company is overlooked by biotechnology investors. He may not have that...
Senate sets date to vet RFK Jr.’s nomination to lead HHS
Prominent vaccine skeptic Robert F. Kennedy Jr. will testify before the Senate Finance Committee on Jan. 29 as he attempts...
Mixed results for Keytruda; AbbVie to work with Neomorph
Today, a brief rundown of news involving Merck & Co. and AstraZeneca, as well as updates from AbbVie, Stealth BioTherapeutics...
The biopharma industry outlook on 2025: Uncertainty and change
As the first major drug industry conference each year, the J.P. Morgan Healthcare Conference is regularly described as a barometer...
Sara Brenner, FDA device official, named agency’s acting head
Sara Brenner, a Food and Drug Administration official within the agency’s medical device division, has been named the FDA’s acting...
Novo shares climb on early data for dual-acting obesity drug
Dive Brief: An experimental obesity drug from Novo Nordisk helped people lose an average of up to 22% of their...
Ascentage prices first biotech IPO of 2025, raising $126M
Dive Brief: Ascentage Pharma, a cancer drug developer based in Suzhou, China, on Thursday raised just over $126 million in...
AI in medtech is taking off. Here are 4 trends to watch in 2025.
Artificial intelligence was a topic of focus for the medical device industry in 2024. Companies including GE Healthcare, Medtronic and...
J&J joins Pfizer in detailing impact of Part D redesign
Johnson & Johnson expects changes in Medicare’s prescription drug benefit will negatively impact its sales by about $2 billion this...
Moderna gets $590M from US government for bird flu vaccine
Moderna will receive some $590 million from the U.S. government to develop messenger RNA vaccines for influenza strains, such as...
AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer
Dive Brief: The Food and Drug Administration on Friday approved AstraZeneca and Daiichi Sankyo’s Datroway for use in people with...
What will 2025 hold for biopharma?
Will 2025 herald a sudden turnaround for biopharma? Unlikely, but continued recovery is likely with some strong growth in therapy...
Federal watchdog cites concerns with FDA’s accelerated approval process
Dive Brief: The Food and Drug Administration needs stricter standards for the accelerated approval process to ensure patients and the...
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
SAN FRANCISCO — With the close of J.P. Morgan Healthcare Conference, attention turns to next week’s inauguration of President-elect Donald...
Lilly’s Omvoh approved by FDA for Crohn’s
Dive Brief: Eli Lilly won Food and Drug Administration approval to sell its Omvoh medicine for adults with Crohn’s disease,...
Ozempic, Ibrance among next drugs picked by Medicare for price talks
Semaglutide, the popular drug sold by Novo Nordisk as Ozempic for diabetes and Wegovy for weight loss, is among a...
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs
Today, a brief rundown of news involving Novo Nordisk and AstraZeneca, as well as updates from Amgen, Atara Biotherapeutics and...
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Medicare’s next drug price negotiations will treat Novo Nordisk’s semaglutide as a single product, regardless of whether the metabolic disease...
Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world
Roche has a big problem. With competition threatening some of its older and most lucrative biologic drugs, the Swiss pharmaceutical...
‘The bar has risen’: China’s biotech gains push US companies to adapt
Soon after starting a new biotechnology company, David Li realized he needed to rethink his strategy. Li had been conducting...
J&J files a potential blockbuster; Lykos shakes up its board
This week, the J.P. Morgan Healthcare Conference has brought a torrent of updates from drugmakers large and small. We’re highlighting...
At JPM, Biogen CEO tries to take down the deal temperature
On Tuesday morning, Biogen hosted an event for Wall Street analysts to better understand the company. One of the key...
JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning
For any hopes the dealmaking that started the J.P. Morgan Healthcare Conference would give the overall biotechnology sector a running...
Lilly blames slower-than-expected growth for 2024 sales miss
Dive Brief: Eli Lilly on Tuesday said the company’s revenue in 2024 totaled about $45 billion, a 32% jump on...
JPM25: Deals, Summit’s bravado and gene therapy headwinds
Every January, the Westin St. Francis in San Francisco is, for a few days, the center of the universe for...
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Late last week, Biogen made an unsolicited offer to buy one of its partners, brain drug developer Sage Therapeutics. The...
Tune raises $175M for hepatitis B medicine, epigenetic research
Genetic medicine startup Tune Therapeutics has raised another $175 million to develop therapies capable of “tuning” genes to treat disease,...
Bayer says menopause drug succeeds in breast cancer study
Dive Brief: An experimental menopause drug from Bayer succeeded in a late-stage trial in women taking drugs to treat or...
Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease
Dive Brief: Ouro Medicines, a new biotechnology startup, launched Friday with $120 million in funding to develop antibody drugs for...
Intellia to stop work on rare disease therapy, lay off staff
Dive Brief: Intellia Therapeutics will stop work on one of its principal drug research programs and lay off more than...
Patrizia Cavazzoni, key FDA official, to leave agency
Patrizia Cavazzoni, an influential Food and Drug Administration official who oversees much of the agency’s drug review work, will leave...
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets
Today, a brief rundown of news involving Pfizer, AbbVie and Royalty Pharma, as well as updates from Biogen and Alkeus...
IGM’s autoimmune pivot backfires as top drug disappoints in testing
IGM Biosciences will scrap its top two drugs and lay off nearly three-quarters of its workforce after reporting study results...
5 questions facing pharma in 2025
Typically, the election of a Republican to the White House is welcome news for the biotechnology and pharmaceutical sectors. The...
Kidney disease drugmaker Maze files for IPO
Maze Therapeutics on Tuesday filed plans for an initial public offering that could become the biotechnology sector’s first of the...
FDA adds warning to RSV shots from GSK, Pfizer
GSK’s and Pfizer’s vaccines for respiratory syncytial virus must carry labels warning of a possible increased risk of a rare...
Vertex, startup Orna to partner on gene editing research
Dive Brief: Vertex Pharmaceuticals will work together with Orna Therapeutics over the next three years to develop technology that would...
ALS drugs from Denali, Calico come up short, marking more failures for Healey trial
A landmark study hoping to find new treatments for ALS has notched two more failures, as experimental medicines from Denali...
An evolution in leadership and vision for this pharma company
About four years ago, Sheldon Koenig was thinking about retiring. After spending decades in leadership roles at different pharmaceutical companies,...
Orbis raises $93M to turn popular biologics into pills
Dive Brief: Orbis Medicines, a European biotechnology startup, has raised 90 million euros, or about $93 million, in a Series...
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
The Food and Drug Administration ended 2024 with a quartet of notable drug approvals, including three of new medicines that...
Neumora plummets on depression drug data
Neumora Therapeutics, a well-funded biotechnology company, lost more than 80% of its value Thursday because its most advanced drug failed...
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals
Happy New Year! We hope you had a restful holiday; If you took a break from keeping up with biotech...
10 clinical trials to watch in the first half of 2025
Incretin drugs have been so successful in clinical testing they’re akin to a pharmaceutical Swiss Army knife. Already, medicines from...
Ottimo raises $140M to compete in chase for new type of cancer drug
David Epstein was ready to retire when an opportunity came along he couldn’t pass up. Epstein had just sold Seagen,...
Zepbound, Mounjaro shortages are resolved, FDA confirms
The Food and Drug Administration on Thursday reaffirmed its assessment that Mounjaro and Zepbound, popular drugs for diabetes and obesity,...
Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint
Vertex Pharmaceuticals lost more than $15 billion in value Thursday as new data on its closely watched pain drug disappointed...
Regeneron says study data support big bet on new blood thinners
Dive Brief: Regeneron Pharmaceuticals intends to advance two blood-thinning drugs into Phase 3 testing next year after mid-stage study results...
A venture firm breathes new life into an old NGM drug
KdT Ventures is launching a new biotechnology startup based on a drug it’s licensing from NGM Biopharmaceuticals, the companies announced...
Novo’s next-gen obesity drug misses expectations in closely watched trial
A new type of obesity drug being developed by Novo Nordisk has fallen short of expectations set by the company...
Ionis gets a milestone approval; Another top FDA official to step down
Today, a brief rundown of news involving Ionis Pharmaceuticals and the Food and Drug Administration, as well as updates from...
Roche sticks with Parkinson’s drug despite second study failure
An experimental drug for Parkinson’s disease that Roche has been developing for more than a decade just flunked another key...
Novartis shutters MorphoSys sites, lays off staff
Swiss pharmaceutical company Novartis plans to close MorphoSys sites in the U.S. and Germany in a “strategic decision” that will...
Merck moves into obesity with deal for Hansoh’s GLP-1 pill
Dive Brief: Merck & Co. has made its first big move in obesity treatment, announcing Wednesday it is paying Hansoh...
A Vertex partner — and potential rival — secures $100M to develop non-opioid pain drugs
Almost 15 years ago, in the midst of an opioid epidemic that would kill more than half a million people...
Namandjé Bumpus, FDA’s No. 2 official, to depart agency at end of year
Namandjé Bumpus, the Food and Drug Administration’s second-in-command, will depart the regulator at the end of the year, according to...
Sanofi, Teva say study results show gut disease drug could be ‘best in class’
Dive Brief: An experimental drug co-developed by Teva and Sanofi met its main objectives in a mid-stage clinical trial in...
Jazz to search for new chief as CEO plans retirement
Jazz Pharmaceuticals on Monday said it will begin searching for a successor to CEO Bruce Cozadd, who plans to retire...
Novo Holdings’ purchase of Catalent set to close after regulators’ green light
Dive Brief: Novo Holdings can complete its $16.5 billion acquisition of contract drug manufacturer Catalent after antitrust regulators in the...
‘Research that’s desperately needed’: White House conference spotlights women’s health
Research into women’s health has long gone underfunded in the U.S. But there’s some optimism that might be changing, attendees...
AbbVie to acquire Roche spinout Nimble in immune drug deal
Dive Brief: AbbVie will pay $200 million to acquire privately held Nimble Therapeutics and its pipeline of oral peptide drugs...
Dietmar Berger is Gilead’s new CMO; Padlock investors sue Bristol Myers
Today, a brief rundown of news involving Gilead and Padlock Therapeutics, as well as updates from Boundless Bio, Lonza and Bausch...
FDA panel seeks more data on RSV vaccine safety in infants
A panel of experts convened by the Food and Drug Administration called for more data to be collected on the...
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
In a rare move, the U.S. agency behind Medicare is warning insurers who provide Medicare Advantage plans that they can’t...
FDA flags additional injury risk for Intercept’s liver drug
The Food and Drug Administration has identified additional safety concerns associated with use of a drug used to treat a...
Editas to lay off staff after search for sickle cell partner comes up empty
Dive Brief: Editas Medicine will lay off 180 employees, or about two-thirds of its workforce, over the next six months...
Q32 Bio battered by study failure of immune drug
Dive Brief: Shares of Q32 Bio lost two-thirds of their value Wednesday after the company reported disappointing study results for...
With new data, Lilly sets pace for next wave of breast cancer drugs
An experimental breast cancer drug developed by Eli Lilly met its main goal in a Phase 3 study, helping people...
Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery
Epigenetic editing startup Chroma Medicine is merging with Nvelop Therapeutics in a deal that will also bring in $75 million...
ASH24: Leukemia drug sequencing, sickle cell questions and a new kind of CAR-T
The American Society of Hematology’s annual meeting continued Monday with important presentations and discussions on the latest blood disease research,...
Gene therapy uptake in sickle cell stays slow, despite patient interest
One year on from the landmark U.S. approval of two powerfully effective gene therapies for sickle cell disease, the treatments...
ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug
This weekend, thousands of researchers and physicians descended on San Diego for the American Society of Hematology’s annual meeting. While...
Clinical services organizations are critical to the future of pharma in the APAC market
Contract development and manufacturing in the Asia-Pacific (APAC) market is poised for explosive growth. The region has been the focus...
GSK taps a startup for shot at Alzheimer’s drug
Inside every human cell are thousands of snippets of genetic code that serve as the directions for creating proteins. And...
AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B
Today, a brief rundown of news involving Daiichi Sankyo, Agenus and Amgen, as well as updates from the U.S. PTO,...
BioAge shares tumble after decision to halt obesity drug study
Dive Brief: BioAge Labs said it is terminating a mid-stage study of its obesity drug candidate azelaprag in combination with...
Lilly adds to obesity drug production push with $3B investment
Eli Lilly will spend $3 billion to expand a manufacturing facility in Wisconsin it bought in April, adding new capabilities...
With conflicts of interest in focus, Trump’s pick to run FDA could face scrutiny of his own industry ties
Robert F. Kennedy Jr., chosen by President-elect Donald Trump to be the next health secretary, has made it his mission...
Nuvig pulls in $161M to make better immune drugs
Biotechnology startup Nuvig Therapeutics is the latest emerging immune drug developer to attract investors’ attention, announcing Thursday a $161 million...
Atlas doubles down on ‘disciplined’ biotech investing with latest fundraise
Dive Brief: Atlas Venture said Thursday that it’s raised $450 million for its 14th fund, through which the firm will...
Atea plans Phase 3 study for hepatitis C drug after mid-stage results
Dive Brief: Atea Pharmaceuticals said Wednesday that its experimental combination regimen to treat the hepatitis C virus succeeded in a...
Dewpoint, Mitsubishi partner on ALS drug in deal worth up to $480M
Dewpoint Therapeutics, a young biotechnology company, could receive nearly half a billion dollars if all goes to plan in a...
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M
Coherus BioSciences has reached a deal to sell another one of its biosimilars as part of a plan to make...
Janux impresses Wall Street with new prostate cancer drug results
Shares of Janux Therapeutics surged to record highs following the release of study results for a drug that, if ultimately...
Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date
Today, a brief rundown of news involving Novocure and Merus, as well as updates from Cytokinetics, Fate Therapeutics and Bluebird...
Diabetes advocacy group discourages use of compounded GLP-1 drugs
The American Diabetes Association, a high-profile advocacy group, is warning against widespread use of compounded versions of popular weight loss...
Are You Using Next-Gen Sequencing to inform AAV product and process quality? Here are 4 reasons you should
Evolving technology has helped advance the field of gene therapy, and today, more and more biopharmaceutical innovators are using groundbreaking...
Alector turns to layoffs as Alzheimer’s drug fails
Brain drug developer Alector is laying off staff after one of its most advanced experimental medicines failed to show enough...
Roche to buy cell therapy developer Poseida for $1B
Swiss pharmaceutical giant Roche is spending around $1 billion to acquire a San Diego-based biotechnology company that’s trying to treat...
Roche’s TIGIT-targeting drug for cancer fails its biggest test
Roche’s long-running bet on a new kind of cancer immunotherapy has, after years of shrinking optimism and second-guessing by analysts...
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Today, a brief rundown of news involving Kronos Bio, Idorsia and PTC Therapeutics, as well as updates from Alnylam Pharmaceuticals...
Sarepta rebuilds drug pipeline with Arrowhead deal
Dive Brief: Sarepta Therapeutics has turned to dealmaking to restock a drug pipeline analysts worried was growing thin, announcing Tuesday...
How Intra-Cellular surprised Wall Street by breaking character
For drug companies, predicting how much money a product will make is a risky endeavor. If the estimate ends up...
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Dive Brief: Amgen on Tuesday said its weight loss drug MariTide helped people with obesity lose up to 20% of...
Biden administration proposes Medicare, Medicaid coverage of pricey weight loss drugs
The Biden administration on Tuesday proposed a rule that would allow Medicare and Medicaid to cover weight loss drugs for...
Biohaven muscle drug misses goal of SMA study, but advances in obesity
Dive Brief: An experimental, muscle-preserving drug from Biohaven fell short of its goal in a Phase 3 study of people...
New data could help Merck expand use of cardiovascular drug
Dive Brief: Adding Merck & Co.’s new cardiovascular drug Winrevair to background therapy helped people with severe lung hypertension stay...
Amgen picks prolific biotech founder Chang as new top scientist
Howard Chang, a top biotechnology researcher and longtime professor at Stanford University, will join Amgen as chief scientific officer on...
Will Walgreens’ store closures disrupt its clinical trial aims?
Retail pharmacy giants have been straining under the intense headwinds hitting the industry this year — and Walgreens’ most recent...
Lexicon to disband sales team, lay off 60% of staff
Dive Brief: Lexicon Pharmaceuticals will lay off 60% of its workforce and eliminate its commercial organization in a restructuring meant...
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
The Food and Drug Administration has approved a new medicine for a deadly genetic heart condition, boosting its developer, BridgeBio...
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA
President-elect Donald Trump on Friday named Johns Hopkins University surgeon Marty Makary to lead the Food and Drug Administration, choosing...
Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial
Today, a brief rundown of news involving Halozyme and Neurogene, as well as updates from Argenx and Kura Oncology that...
Novartis wagers more than $1B on gene therapies for the nervous system
Through a new deal, Novartis has added a handful of experimental gene therapies to its neuroscience research pipeline. Novartis is...
Biotech startups are built on venture capital. Track funding rounds here.
Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if...
Pfizer, under pressure to change, names oncology head as new R&D chief
Pfizer on Wednesday said it will promote Chris Boshoff to chief scientific officer and president of research and development as...
Sage’s string of research failures continues
Sage Therapeutics is shelving one of its most important experimental drugs, after a last-ditch effort to prove it can be...
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
Today, a brief rundown of news involving Astellas and Cytokinetics, as well as updates from Cybin, Neurogene and Novartis that...
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
Dive Brief: An experimental under-the-skin injection of Merck & Co.’s cancer immunotherapy Keytruda showed similar characteristics as the current intravenous...
Syndax secures FDA OK for new kind of leukemia drug
Dive Brief: Massachusetts-based Syndax Pharmaceuticals won Food and Drug Administration approval Friday for a new kind of drug to treat an...
Leveraging NGS to move precision oncology forward, from CDx to commercialization
Advances in precision oncology have allowed patients to access innovative life-saving therapies when they previously had few, or no, other...
PTC wins US approval of gene therapy for fatal enzyme disorder
Dive Brief: PTC Therapeutics on Wednesday won Food and Drug Adminitration approval for Kebilidi, the first gene therapy cleared in...
Halozyme bids for Evotec; BeiGene gets a new name
Today, a brief rundown of news involving Evotec, Bluebird bio and the company formerly known as BeiGene, as well as...
Surviving in biotech’s new normal: 5 tips from industry VCs and CEOs
Market downturns take a toll. For many young biotechnology companies, the past few years have been a lesson in survival,...
‘Find any advantage’: 3 biotech leaders on driving R&D success
Failure is more common than success for young biotechnology companies attempting to get a new drug onto the market. Drug...
How a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, a freshly launched startup, is developing a type of genetic medicine it believes could help most, if not...
Eisai wins over European regulators on Alzheimer’s drug Leqembi
In an unusual reversal, key drug regulators in Europe are now saying Leqembi, a high-profile medicine for Alzheimer’s disease, should...
Trump names RFK Jr. as his pick to lead HHS
President-elect Donald Trump plans to nominate Robert F. Kennedy Jr. to lead the Department of Health and Human Services in...
Metsera raises $215M to accelerate obesity drug plans
Dive Brief: Metsera, already a well-funded biotech startup, added another $215 million to its coffers as investors responded to the...
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
Today, a brief rundown of news involving Amgen and AstraZeneca, as well as updates from Roche, Novartis, and Centessa Pharmaceuticals...
Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS
Third Rock Ventures, the well-known backer of biotechnology companies, is leading a nine-figure fundraising round for a startup that aims...
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Flagship Pioneering startup Vesalius Therapeutics has signed a deal with GSK, the companies announced Tuesday, for the British pharma to...
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Through a recent, nearly $9 billion acquisition, AbbVie surged to the front of a new wave of antipsychotic drugs that...
FDA approves new CAR-T competitor to Gilead’s Tecartus
Dive Brief: The Food and Drug Administration on Friday approved a new cell therapy for a type of leukemia. Called...
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale
Today, a brief rundown of news from Moderna, Intra-Cellular Therapies and Vertex Pharmaceuticals, as well as updates from Syndax Pharmaceuticals...
With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC
Donald Trump’s victory in the U.S. presidential election Tuesday means change is coming for federal health agencies and the industries...
What RFK Jr.’s influence on Trump could mean for pharma
With the U.S. presidential election decided, one name is suddenly circulating in healthcare: Robert F. Kennedy Jr. President-elect Donald Trump...
Athira exploring strategic alternatives after Alzheimer’s failure
Dive Brief: Athira Pharma, a small drugmaker focused on neuroscience, is looking into the different paths it could take to...
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
Today, a brief rundown of news from AstraZeneca, Amgen and Jazz Pharmaceuticals, as well as updates from Geron, Gilead Sciences...
Kalaris to go public via reverse merger with AlloVir
Public biotechnology company AlloVir has agreed to merge with the privately held Kalaris Therapeutics, nearly one year after a clinical...
Sarepta scraps a Duchenne drug as gene therapy sales rise
Dive Brief: Sarepta Therapeutics is giving up on an experimental drug for Duchenne muscular dystrophy as sales rocket for its...
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Dive Brief: Moderna on Thursday reported third quarter sales of its COVID-19 vaccine that substantially outperformed analyst expectations. The company...
Acadia sells speedy drug review voucher for $150M
Acadia Pharmaceuticals agreed to sell a priority review voucher to an undisclosed buyer for $150 million, a price tag on...
Novo sees Wegovy sales rise as supply constraints ease
Dive Brief: Dive Insight: Novo and Lilly are racing to build on their dominant obesity drug businesses. Both are working...
Cancer cell therapy from Arcellx, Gilead shows promise in early data
Dive Brief: A cancer cell therapy developed by Arcellx and Gilead Sciences helped reduce or eliminate signs of multiple myeloma...
Sana to lay off staff, deepen autoimmune focus in latest retrenchment
Sana Biotechnology will lay off staff and shift its research focus in the latest retrenchment for a company only three...
Neurogene secures $200M ahead of anticipated study readout
Neurogene, a gene therapy developer focused on rare neurological diseases, has secured $200 million through a private funding deal that...
Empowering versatile applications of digital PCR with standardized, validated assays
As the third generation of PCR technology, digital PCR introduced powerful new capabilities to countless research applications. Features such as...
FDA’s new device chief faces challenges. Patient groups, industry are still optimistic.
Michelle Tarver, the new leader of the Food and Drug Administration’s medical device center, faces significant challenges. Tarver is taking...
Evommune raises $115M to accelerate immune drug tests
California biotechnology startup Evommune has raised $115 million to advance a pair of medicines it’s developing for chronic immune conditions....
Compass delays anticipated psilocybin readout, cuts staff
Dive Brief: Compass Pathways said it will lay off 30% of its workforce, narrow its research focus and explore selling...
Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug
Today, a brief rundown of news from Regeneron Pharmaceuticals and Madrigal Pharmaceuticals, as well as updates from UCB, AbbVie and...
Novo, with new results, to seek approval for obesity drug in MASH
Novo Nordisk will seek regulatory approval of semaglutide, the key ingredient in its popular weight loss medicine, in a common...
Jade, another biotech spinout of Paragon, to merge with Aerovate
Dive Brief: Jade Biosciences, a privately held developer of immune disease drugs, will combine with Aerovate Therapeutics in a reverse...
Roche weighs whether speedy approval path is open for latest Alzheimer’s drug
Dive Brief: Roche may seek an accelerated U.S. approval of its experimental Alzheimer’s disease drug trontinemab if the therapy continues...
GSK vaccine sales sink on lower demand for RSV, shingles shots
Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand, sending shares in the British pharmaceutical...
Novo takes big step toward ending Ozempic, Wegovy shortages
All doses of Novo Nordisk's popular GLP-1 medicines Ozempic and Wegovy are available in the U.S. and being regularly shipped...
A new biotech, built around protein design, springs from David Baker’s lab
Archon Biosciences came about as most startups do, the result of happenstance and good timing. Unlike many, the biotechnology company...
Pfizer sales of RSV vaccine ebb, but company gains market share
Sales of Pfizer’s new vaccine for respiratory syncytial virus were lower in the third quarter than during the same period...
Monte Rosa joins with Novartis in ‘molecular glue’ drug deal
Dive Brief: Novartis will pay $150 million to gain rights to “molecular glue degraders” being developed by biotechnology company Monte...
AbbVie to acquire a J&J-backed brain drugmaker for $1.4B
AbbVie has agreed to acquire a young company with drugmaking technology from Johnson & Johnson and an experimental treatment for...
Don’t let your samples slip: Why every clinical trial needs biospecimen management
Managing biospecimens is a critical, yet often overlooked, part of ensuring a clinical trial’s success. Biospecimen managers are a resource...
With $92M, Kivu sets out to make ‘kinder, gentler’ ADCs
Dive Brief: Kivu Biosciences, a San Francisco-based biotechnology startup developing targeted drugs for cancer, has raised $92 million in a...
Intellia data spark debate about CRISPR drug’s potential
Dive Brief: Intellia Therapeutics on Thursday released detailed Phase 2 results from a study of a gene-editing therapy for hereditary...
Merck, Pfizer lifted as CDC backs broader use of pneumococcal vaccines
A panel of advisers to the Centers for Disease Control and Prevention on Wednesday recommended lowering the age for routine...
GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
Today, a brief rundown of news from GSK and Amgen, as well as updates from Roche, AbbVie, and Marinus Pharmaceuticals...
Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of...
GPCR drugmaker Septerna amasses $288M in IPO
Septerna, a developer of medicines that target a ubiquitous family of proteins, on Thursday priced a $288 million initial public...
Lyell, in search of a turnaround, to buy cell therapy startup ImmPact
Lyell Immunopharma, a cell therapy developer that has struggled to match its high profile, is acquiring a biotechnology startup and...
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Dive Brief: The Food and Drug Administration on Tuesday expanded the approval of Pfizer’s RSV vaccine Abrysvo to include adults...
Alto hits new low as depression drug flunks key test
Alto Neuroscience, a young biotechnology company developing medicines for the brain, lost much of its value Wednesday as negative results...
FDA names Tarver as new head of device center
The Food and Drug Administration on Tuesday named Michelle Tarver as the permanent director of the agency’s device center. Tarver...
Sanofi moves ahead with CD&R deal for stake in consumer business
Dive Brief: French pharmaceutical company Sanofi is proceeding with plans to sell U.S.-based private equity firm Clayton Dubilier & Rice...
PureTech thinks the ‘hub-and-spoke’ startup model is still a good bet. If only investors agreed.
Biotechnology investors dream of success stories like Karuna Therapeutics. Founded in 2009, the company took a drug others had given...
Sanofi, expanding in radiopharma, strikes a joint venture deal
Dive Brief: Sanofi will invest 300 million euros, or about $325 million, for a roughly 16% stake in a new...
After rejections, AbbVie secures approval for Parkinson’s drug
People with advanced Parkinson’s disease have a new treatment option, as the Food and Drug Administration on Thursday approved a...
